XML 32 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation and Significant Accounting Policies (Narrative) (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2010
right
Sep. 30, 2016
USD ($)
shares
Sep. 30, 2015
USD ($)
shares
Sep. 30, 2016
USD ($)
segment
shares
Sep. 30, 2015
USD ($)
shares
Dec. 31, 2015
USD ($)
Aug. 31, 2014
USD ($)
Property, Plant and Equipment [Line Items]              
Number of operating segments | segment       1      
Earnings (Loss) Per Share              
Common shares excluded from computation | shares   3,540,806 3,343,719 3,522,063 3,803,007    
Cash, Cash Equivalents and Short-term Investments              
Maturity period of cash and cash equivalents, maximum       3 months      
Maturity period of short term investments, minimum       3 months      
Inventory, Net [Abstract]              
Inventory write downs   $ 0 $ 0 $ 0 $ 0    
Property and Equipment              
Depreciation       100,000 100,000    
Contingent Liabilities              
Purchase of commercial license rights       92,504,000 0    
Lease Obligations              
Lease exit obligations   0   $ 0   $ 934,000  
Equipment | Minimum              
Property and Equipment              
Estimated useful life of assets       3 years      
Equipment | Maximum              
Property and Equipment              
Estimated useful life of assets       10 years      
Cydex Pharmaceuticals, Inc              
Contingent Liabilities              
Fair value of liability   6,700,000   $ 6,700,000   9,500,000  
Contingent liability change in amount   (1,200,000) (900,000) (1,600,000) (3,100,000)    
Cydex Pharmaceuticals, Inc | Revenue Sharing              
Contingent Liabilities              
Purchase of commercial license rights   1,400,000 800,000 4,400,000 3,900,000    
Metabasis Therapeutics              
Contingent Liabilities              
Fair value of liability   2,300,000   2,300,000   4,000,000  
Contingent liability change in amount   (200,000) (3,200,000) 1,000,000 1,900,000    
Number of contingent value rights | right 4            
Number of contingent value rights per series of contingent value rights | right 1            
Number of contingent value rights issued for each share | right 4            
Contingent value rights, frequency of cash payment 6 months            
Contingent liability, cash payment   0 $ 500,000 2,600,000 $ 800,000    
2019 convertible senior notes              
Convertible Debt              
Principal amount outstanding   $ 245,000,000   $ 245,000,000   $ 245,000,000  
2019 convertible senior notes | Senior Notes              
Convertible Debt              
Principal amount outstanding             $ 245,000,000.0
Interest rate             0.75%
Director              
Relationships between the CorMatrix Parties              
Mr. Aryeh's owenership percentage in CorMatrix (percent, less than)   1.00%   1.00%